



# *CACHD1: a new activity-modifying protein for voltage-gated calcium channels*

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open access

Stephens, G. J. and Cottrell, G. S. (2019) CACHD1: a new activity-modifying protein for voltage-gated calcium channels. *Channels*, 13 (1). pp. 120-123. ISSN 1933-6969 doi: <https://doi.org/10.1080/19336950.2019.1600968> Available at <http://centaur.reading.ac.uk/83274/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1080/19336950.2019.1600968>

Publisher: Taylor & Francis

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

**CentAUR**

Central Archive at the University of Reading

Reading's research outputs online





## CACHD1: A new activity-modifying protein for voltage-gated calcium channels

Gary J. Stephens & Graeme S. Cottrell

To cite this article: Gary J. Stephens & Graeme S. Cottrell (2019) CACHD1: A new activity-modifying protein for voltage-gated calcium channels, Channels, 13:1, 120-123, DOI: [10.1080/19336950.2019.1600968](https://doi.org/10.1080/19336950.2019.1600968)

To link to this article: <https://doi.org/10.1080/19336950.2019.1600968>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 13 Apr 2019.





Submit your article to this journal [↗](#)



View Crossmark data [↗](#)

## CACHD1: A new activity-modifying protein for voltage-gated calcium channels

Gary J. Stephens  and Graeme S. Cottrell 

School of Pharmacy, University of Reading, Reading, UK

**ARTICLE HISTORY** Received 20 March 2019; Accepted 22 March 2019

Understanding the mechanisms that regulate the trafficking and expression of voltage-gated calcium channels (VGCCs) at presynaptic and potentially postsynaptic plasma membrane microdomains is of paramount importance. VGCCs are subdivided into two main families: high voltage-activated calcium channels (HVACCs) and low voltage-activated calcium channels (LVACCs) (reviewed [1]). HVACCs comprise  $Ca_v1.1-4$  (L-type current),  $Ca_v2.1$  (P/Q-type current),  $Ca_v2.2$  (N-type current) and  $Ca_v2.3$  (R-type current) VGCCs, whereas LVACCs comprise the  $Ca_v3$  (T-type current) family. The expression, assembly, localization and biophysical properties of HVACCs can be modulated by  $\alpha_2\delta$  and  $\beta$  auxiliary subunits. However, the modulation of  $Ca_v3$  channels by other proteins has remained less well defined.  $\alpha_2\delta$  and  $\beta$  subunits are not considered to be auxiliary subunits for  $Ca_v3$  subunits and consensus opinion is that  $Ca_v3$  can form fully functional channels alone (reviewed [2]). We have recently identified CACHD1 (Ca<sup>2+</sup> channel and chemotaxis receptor (cache) domain containing protein 1), a protein with structural similarities to the  $\alpha_2\delta$  family, as a modulator of  $Ca_v3$  VGCC activity in expression systems and in native neurons [3]. Our study adds to other recently defined modulators of  $Ca_v3$  subunits which include endogenous molecules such as the actin binding protein kelch-like 1 (KLHL1), the Stac adaptor protein 1 (Stac1), the endoplasmic reticulum integral membrane protein, calnexin and the ubiquitin-specific protease, USP5 (reviewed [4]).

Primary sequence analysis reveals that although CACHD1 has limited sequence identity to  $\alpha_2\delta$  subunits, it similarly contains a VWA (von Willebrand Factor A) domain and putative bacterial


chemosensory-like cache domains (Figure 1). However, there are a number of important differences compared to  $\alpha_2\delta$  subunits that will potentially affect CACHD1 function. For example, CACHD1 contains fewer predicted glycosylation sites, a variant metal ion-dependent adhesion site (MIDAS) motif (D<sup>234</sup>XGX<sup>S</sup>) within the VWA domain and a variant gabapentin binding site (R<sup>213</sup>-S-R). Of potential importance, CACHD1 is predicted to be a single transmembrane protein with a large intracellular C-terminal tail, unlike  $\alpha_2\delta$ , which is reportedly a glycosylphosphatidylinositol (GPI)-anchored protein (reviewed [2]). In our study, we demonstrated that CACHD1 promoted the cell surface localization of  $Ca_v3.1$  in a heterologous expression system [3]. Furthermore, using proximity ligation assays, we showed that CACHD1 and  $Ca_v3.1$  are <40 nm apart at the cell surface, supporting the formation of CACHD1- $Ca_v3.1$  complexes at the plasma membrane. Our electrophoretic analyses indicated that CACHD1 migrated slower than its predicted molecular mass of 142 kDa, migrating at approximately ~170 kDa, possibly indicating post-translational glycosylation. Human CACHD1 was shown to cause clear effects on human  $Ca_v3.1$ ,  $Ca_v3.2$  and  $Ca_v3.3$  subunits, increasing peak current density with a corresponding increase in maximal conductance. In contrast, expression of  $\alpha_2\delta 1$  had no effect on T-type current under the same conditions. CACHD1 increased the open probability of the  $Ca_v3.1$  channel, pointing to mechanistic effects on the  $\alpha_1$  subunit. We further demonstrated functional effects of CACHD1 on native T-type current in rat hippocampal neurons. CACHD1 transfected neurons fired at a higher frequency than control neurons, an effect that was

**CONTACT** Gary J. Stephens  g.j.stephens@reading.ac.uk

Autocommentary to: Cottrell GS, Soubrane CH, Hounshell JA, Lin H, Owenson V, Rigby M, Cox PJ, Barker BS, Ottolini M, Ince S, Bauer, CC, Perez-Reyes E, Patel MK, Stevens EB, Stephens GJ (2018) CACHD1 is an  $\alpha_2\delta$ -like protein that modulates  $Ca_v3$  voltage-gated calcium channel activity *J Neurosci* 38:9186-9201.

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Figure 1. Schematic comparison of the major domains and structural motifs of  $\alpha_2\delta_1$  and CACHD1.** (Left)  $\alpha_2\delta_1$  is translated as a single polypeptide chain that is proteolytically processed into two chains ( $\alpha_2$  and  $\delta$ ), which are covalently connected by a disulphide bridge. The  $\delta$  chain is further processed to tether the protein to the plasma membrane, reportedly via a glycosylphosphatidylinositol anchor (reviewed [2]). Crystallographic studies reveal that the large extracellular facing portion of  $\alpha_2\delta_1$  contains a von Willebrand Factor A (VWA) domain and four cache domains [9]. Within the VWA domain,  $\alpha_2\delta_1$  possesses a consensus metal ion-dependent adhesion site (MIDAS) motif that is important for its interaction with pore-forming  $\alpha_1$  subunits. (Right) CACHD1 is a single polypeptide chain with a large extracellular N-terminal domain, a single transmembrane domain and an intracellular C-terminal tail. Similar to  $\alpha_2\delta_1$ , the extracellular region of CACHD1 contains a single VWA domain. Currently, CACHD1 has two predicted cache domains and contains a variant MIDAS motif within its VWA domain.

prevented by the selective T-type current blocker TTA-P2. Furthermore, CACHD1 caused a significant increase in rebound firing frequency, a property mediated predominantly by T-type current; TTA-P2 similarly reversed this effect. Together, these data support a role for CACHD1 in increasing neuronal T-type current, which in turn promotes an increase in action potential firing frequency and neuronal excitability. The future study of neurons from CACHD1 knockout mice will further advance knowledge of the physiological role of CACHD1.

A subsequent report has also identified a role for CACHD1 as a modulator of other VGCC subtypes, reporting effects on  $\text{Ca}_v2.2$  [5]. Together, these studies suggest that CACHD1 may have broader therapeutic potential. However, although CACHD1 caused a significant increase in  $\text{Ca}_v2.2$  current, this modulation was not as profound as seen for  $\alpha_2\delta_1$ ; indeed, co-expression of CACHD1 caused a reduction in  $\alpha_2\delta_1$ -mediated actions on  $\text{Ca}_v2.2$ . These data indicate that CACHD1 may have a dominant negative-like effect on N-type calcium current and led to the suggestion that

CACHD1 and  $\alpha_2\delta_1$  may compete for the same structural motif on  $\text{Ca}_v2.2$  [5], unlike the situation for  $\text{Ca}_v3$  subunits. In our original studies, we did not detect any significant increase in  $\text{Ca}^{2+}$  current for human  $\text{Ca}_v2.2$  co-expressed with human CACHD1 [6], in contrast to effects reported for rat  $\text{Ca}_v2.2$  with zebrafish or rat CACHD1 [5]. Of further interest was that these CACHD1 orthologues had no effect on rat  $\text{Ca}_v2.1$  [5]. Therefore, it may be that CACHD1 effects are dependent on the species of both CACHD1 and the  $\alpha_1$  subunit.

The  $\alpha_2\delta$  MIDAS motif (DxSxS) within its VWA domain plays a major role in their modulation of VGCC function (reviewed [2]). Approximately 46% of VWA domain-containing proteins contain a conserved MIDAS motif [7]. CACHD1 has a variant MIDAS motif (D<sup>234</sup>xGxS). Of functional importance, structural studies of VWA domains and biochemical analysis of a family of proteins called copines revealed that a perfectly conserved MIDAS motif is not required for metal ion binding [7]. Due to the difficulties of predicting non-contiguous structural motifs, such as cache domains, from

primary sequences, it remains undetermined if the downstream Thr and Asp residues in human CACHD1 contribute to a conserved MIDAS motif. However, one could speculate, based on our preliminary sequence alignments, that these residues are Thr<sup>311</sup> and Asp<sup>338</sup>. Mutation of the Asp and Ser residues to Ala (AxAxA) in the  $\alpha_2\delta_1$  MIDAS motif caused disruption of the interaction between  $\alpha_2\delta_1$  and Ca<sub>v</sub>2.2 and this interaction was also prevented by mutation of Asp<sup>122</sup> to Ala on Ca<sub>v</sub>2.2 [5]; surprisingly, the D122A mutation did not prevent CACHD1-mediated enhancement of Ca<sub>v</sub>2.2 currents. This data may indicate that CACHD1 does not interact with Ca<sub>v</sub>2.2 in exactly the same way as  $\alpha_2\delta_1$ . Future biochemical and electrophysiological studies involving mutated forms of the CACHD1 variant MIDAS motif will shed light on its role in the regulation of the function of both CACHD1 and VGCCs. The electrophoretic mobility of rat CACHD1 was increased to its predicted level by treatment of whole cell lysates with the N-linked deglycosylating enzyme, PNGase F, indicating that rat CACHD1 is modified by N-linked glycosylation [5]. This study highlighted seven high potential N-linked glycosylation sites on rat CACHD1. Similar sequence analysis of human CACHD1 reveals one very high probability site (Asn<sup>145</sup>), five other high probability Asn residues, with an additional three lower potential sites. Future experimentation will reveal precisely which residues are glycosylated and the role of glycosylation in the function of human CACHD1.

To date, CACHD1 and the  $\alpha_2\delta$  isoforms are the only mammalian proteins known to contain bacterial chemosensory-like cache domains. Cache domains are the most important extracellular sensors in prokaryotes (reviewed [8]) and may represent potential drug targets. The current predicted CACHD1 structure, including two predicted cache domains, is based on extant Uniprot data (Q5VU97). For  $\alpha_2\delta_1$ , the initial description of a single cache domain (Uniprot data, P54289) has been revised to two and most recently to four domains following the latest crystal structure at 3.6 Å [9]. A similar crystal structure will be required to determine the number of cache domains in CACHD1, but the presence of multiple cache domains adds another dimension to the possible functionality of both  $\alpha_2\delta$  and CACHD1.

With regard to our recent work, CACHD1 is predicted to act mechanistically to increase Ca<sub>v</sub>3 channel open probability and promote T-type currents. Such physiological actions may have implications in targeting diseases involving aberrant neuronal firing. In particular, Ca<sub>v</sub>3 channels have been proposed as therapeutic targets to combat pain and epilepsy (reviewed [4]). It is of particular interest that CACHD1 transcripts are highly expressed in mouse dorsal root ganglia [10], key transducers of nociceptive information. However, the therapeutic potential of Ca<sub>v</sub>3-targeting drugs remains largely unrealized, as clinical drugs such as ethosuximide lack Ca<sub>v</sub>3 selectivity and an earlier agent, mibefradil, was withdrawn due to serious drug interaction issues. It will be of interest to identify the functions of the domains and sequence motifs present in CACHD1 responsible for its effects on T-type currents and the sequences within Ca<sub>v</sub>3 channels that may participate in the interaction with CACHD1. Targeting proteins such as CACHD1 that modulate Ca<sub>v</sub>3 function may provide an attractive alternative to the direct blocking of the  $\alpha_1$  subunit pore and we propose that CACHD1 represents an important new protein with excellent potential for future therapeutic targeting.

## Disclosure statement

No potential conflict of interest was reported by the authors.

## ORCID

Gary J. Stephens  <http://orcid.org/0000-0002-8966-4238>

Graeme S. Cottrell  <http://orcid.org/0000-0001-9098-7627>

## References

- [1] Zamponi GW, Striessnig J, Koschak A, et al. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. *Pharmacol Rev.* 2015;67:821–870.
- [2] Dolphin AC. Calcium channel auxiliary  $\alpha_2\delta$  and  $\beta$  subunits: trafficking and one step beyond. *Nat Rev Neurosci.* 2012;13:542–555.
- [3] Cottrell GS, Soubrane CH, Hounshell JA, et al. CACHD1 is an  $\alpha_2\delta$ -like protein that modulates Ca<sub>v</sub>3 voltage-gated calcium channel activity. *J Neurosci.* 2018;38:9186–9201.

- [4] Weiss N, Zamponi GW. T-type calcium channels: from molecule to therapeutic opportunities. *Int J Biochem Cell Biol.* [2019](#);108:34–39.
- [5] Dahimene S, Page KM, Kadurin I, et al. The alpha2delta-like protein *cachd1* increases N-type calcium currents and cell surface expression and competes with alpha2delta-1. *Cell Rep.* [2018](#);25:1610–1621 e1615.
- [6] Soubrane CH, Stevens EB, Stephens GJ (2012) Expression and functional studies of the novel CNS protein CACHD1. *Proceedings of The Physiological Society; Edinburgh; Vol. 27, PC74*
- [7] Whittaker CA, Hynes RO. Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. *Mol Biol Cell.* [2002](#);13:3369–3387.
- [8] Anantharaman V, Aravind L. Cache - a signaling domain common to animal Ca<sup>2+</sup>-channel subunits and a class of prokaryotic chemotaxis receptors. *Trends Biochem Sci.* [2000](#);25:535–537.
- [9] Wu J, Yan Z, Li Z, et al. Structure of the voltage-gated calcium channel Ca<sub>v</sub>1.1 at 3.6 Å resolution. *Nature.* [2016](#);537:191–196.
- [10] Ray P, Torck A, Quigley L, et al. Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research. *Pain.* [2018](#);159:1325–1345.